1. 国家自然科学基金，基于新机制双重调控βⅢ与P-gp针对耐药乳腺癌的先导物发现、优化及活性研究，项目号：81903443，20万，2020.01-2022.12，主持，结项。
2. 河南省科技厅，抗新生血管及多药耐药小分子PROTAC的分子构建及机制研究，项目号：192102310146，10万，2019.01-2021.06，主持，结项。
3. 河南省教育厅，tubulin及CDK4/6双靶点抑制剂的发现及生物活性评价，项目号：24A350003，3万，2024.1-2025.12，主持，在研。
4. 河南省教育厅，选择性S1P1受体激动剂的设计与生物活性研究，项目号：15A350005，2万，2015.01-2019.10，主持，结项。
5.开封市科技局，具有c-src激酶降解活性PROTAC构建及活性研究，项目号：2103008,2022.01-2023.12，主持，结项。
1. Hao Wang; Jianfei Ba; Yue Kang; Zeqiao Gong; Tingting Liang; Yahong Zhang; Jianguo Qi; Jianhong Wang. Recent Progress in CDK4/6 Inhibitors and PROTACs, Molecules, 2023, 28(24):8060.
2. Tingting Liang; Xiaomin Zhou; Lu Lu; Haiyang Dong; Yanan Zhang; Yungen Xu; Jianguo Qi;Yahong Zhang; Jianhong Wang ; Structure-activity relationships and antiproliferative effects of 1,2,3,4-4H-quinoxaline derivatives as tubulin polymerization inhibitors, Bioorganic Chemistry, 2021, 110: 104793.
3. Jianguo Qi; Gang Zhang ; Proteolysis-targeting chimeras for targeting protein for degradation, Future Medicinal Chemistry , 2019, 11(7): 723-742.
4. Jianguo Qi; Jing Huang; Xiaomin Zhou; Wen Luo; Jiaxin Xie; Linqiang Niu; Zhijie Yan; Yang Luo; Yuhui Men; Yanan Chen; Yahong Zhang; Jianhong Wang; Synthesis and biological evaluation of quinoxaline derivatives as tubulin polymerization inhibitors that elevate intracellular ROS and triggers apoptosis via mitochondrial pathway, Chemical Biology and Drug Design , 2019, 93(4): 617-627.
5. Jianguo Qi; Haiyang Dong; Jing Huang; Shufeng Zhang; Linqiang Niu; Yahong Zhang; Jianhong Wang; Synthesis and biological evaluation of N-substituted 3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acid derivatives as tubulin polymerization inhibitors, European Journal of Medicinal Chemistry, 2018, 143: 8-20.
